Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-713-3699
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$280.41 million
Profitability
Miscellaneous
Employees266
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions
What is Collegium Pharmaceutical's stock symbol?
Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."
How were Collegium Pharmaceutical's earnings last quarter?
Collegium Pharmaceutical Inc (NASDAQ:COLL) announced its earnings results on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.05. The specialty pharmaceutical company earned $75.04 million during the quarter, compared to analyst estimates of $75.77 million. Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The firm's quarterly revenue was up 2.7% compared to the same quarter last year. During the same period last year, the company posted ($0.40) earnings per share. View Collegium Pharmaceutical's Earnings History.
When is Collegium Pharmaceutical's next earnings date?
What price target have analysts set for COLL?
5 analysts have issued twelve-month target prices for Collegium Pharmaceutical's stock. Their predictions range from $22.00 to $33.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $26.20 in the next twelve months. This suggests a possible upside of 125.1% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.
What is the consensus analysts' recommendation for Collegium Pharmaceutical?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.
Has Collegium Pharmaceutical been receiving favorable news coverage?
Media coverage about COLL stock has been trending negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Collegium Pharmaceutical.
Who are some of Collegium Pharmaceutical's key competitors?
Some companies that are related to Collegium Pharmaceutical include Corcept Therapeutics (CORT), Alder Biopharmaceuticals (ALDR), Madrigal Pharmaceuticals (MDGL), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Gossamer Bio (GOSS), Aimmune Therapeutics (AIMT), Enanta Pharmaceuticals (ENTA), Turning Point Therapeutics (TPTX), G1 Therapeutics (GTHX), Radius Health (RDUS), Theravance Biopharma (TBPH), Opko Health (OPK), BELLUS Health (BLUSF) and Ra Pharmaceuticals (RARX).
What other stocks do shareholders of Collegium Pharmaceutical own?
Who are Collegium Pharmaceutical's key executives?
Collegium Pharmaceutical's management team includes the folowing people:
- Mr. Michael Thomas Heffernan, Co-Founder & Chairman (Age 55)
- Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 48)
- Mr. Paul J. Brannelly, Exec. VP & CFO (Age 46)
- Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 44)
- Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 35)
When did Collegium Pharmaceutical IPO?
(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.
Who are Collegium Pharmaceutical's major shareholders?
Collegium Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (12.95%), Janus Henderson Group PLC (12.95%), BlackRock Inc. (7.43%), Vanguard Group Inc. (4.70%), Rice Hall James & Associates LLC (3.78%) and Morgan Stanley (1.53%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.
Which institutional investors are selling Collegium Pharmaceutical stock?
COLL stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, D. E. Shaw & Co. Inc., A.R.T. Advisors LLC, Morgan Stanley, State Board of Administration of Florida Retirement System, Trexquant Investment LP, Bogle Investment Management L P DE and United Services Automobile Association. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View Insider Buying and Selling for Collegium Pharmaceutical.
Which institutional investors are buying Collegium Pharmaceutical stock?
COLL stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Janus Henderson Group PLC, Renaissance Technologies LLC, Cortina Asset Management LLC, Nuveen Asset Management LLC, BlackRock Inc., Eversept Partners LP and Bank of Montreal Can. View Insider Buying and Selling for Collegium Pharmaceutical.
How do I buy shares of Collegium Pharmaceutical?
Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Collegium Pharmaceutical's stock price today?
One share of COLL stock can currently be purchased for approximately $11.64.
How big of a company is Collegium Pharmaceutical?
Collegium Pharmaceutical has a market capitalization of $389.60 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.
What is Collegium Pharmaceutical's official website?
How can I contact Collegium Pharmaceutical?
Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.
MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days.
